KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Travere Therapeutics' EPS (Weighted Average and Diluted) history spans 13 years, with the latest figure at -$0.25 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 64.79% year-over-year to -$0.25; the TTM value through Dec 2025 reached -$0.58, up 85.78%, while the annual FY2025 figure was -$0.57, 86.03% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.25 in Q4 2025 per TVTX's latest filing, down from $0.28 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.28 in Q3 2025 to a low of -$1.76 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.9, with a median of -$1.0 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 4900.0% in 2021, then surged 140.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.46 in 2021, then rose by 29.45% to -$1.03 in 2022, then fell by 12.62% to -$1.16 in 2023, then surged by 38.79% to -$0.71 in 2024, then soared by 64.79% to -$0.25 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EPS (Weighted Average and Diluted) are -$0.25 (Q4 2025), $0.28 (Q3 2025), and -$0.14 (Q2 2025).